TXMD icon

TherapeuticsMD

1.11 USD
+0.02
1.83%
At close Dec 20, 4:00 PM EST
1 day
1.83%
5 days
-11.90%
1 month
-17.16%
3 months
-35.09%
6 months
-40.00%
Year to date
-52.36%
1 year
-51.95%
5 years
-99.03%
10 years
-99.52%
 

About: TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.

Employees: 1

0
Funds holding %
of 6,809 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

33% more call options, than puts

Call options by funds: $24K | Put options by funds: $18K

2% less capital invested

Capital invested by funds: $5.7M [Q2] → $5.61M (-$90.7K) [Q3]

1.4% less ownership

Funds ownership: 30.71% [Q2] → 29.31% (-1.4%) [Q3]

5% less funds holding

Funds holding: 37 [Q2] → 35 (-2) [Q3]

29% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 7

67% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 6

Research analyst outlook

We haven’t received any recent analyst ratings for TXMD.

Financial journalist opinion

Neutral
Business Wire
1 month ago
TherapeuticsMD Announces Third Quarter 2024 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(567) thousand, or $(0.05) per basic and diluted common share, compared to a net loss of $(1.4) million, or $(0.13) per basic and d.
TherapeuticsMD Announces Third Quarter 2024 Financial Results
Positive
Benzinga
3 months ago
TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying
The Dow Jones index closed higher by more than 450 points on Friday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.
TherapeuticsMD And 2 Other Stocks Under $2 Executives Are Buying
Neutral
Business Wire
4 months ago
TherapeuticsMD Announces Second Quarter 2024 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the second quarter ended June 30, 2024. Second Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(1.05) million, or $(0.09) per basic and diluted common share, compared to a net loss of $(2.4) million, or $(0.24) per basic and dilu.
TherapeuticsMD Announces Second Quarter 2024 Financial Results
Neutral
Business Wire
7 months ago
TherapeuticsMD Announces First Quarter 2024 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Financial Results Net Income (Loss) from Continuing Operations Net loss from continuing operations was $(0.8) million, or $(0.07) per basic and diluted common share, compared to net loss from continuing operations of $(2.3) million, or $(0.
TherapeuticsMD Announces First Quarter 2024 Financial Results
Neutral
Business Wire
8 months ago
TherapeuticsMD Announces Full Year 2023 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the full year ended December 31, 2023. “We continue to explore a variety of strategic alternatives with the goal of maximizing value for our shareholders,” stated Marlan D. Walker, Chief Executive Officer of TherapeuticsMD. Full Year 2023 Financial Results Net Income (Loss) from Continuing Operati.
TherapeuticsMD Announces Full Year 2023 Financial Results
Neutral
Business Wire
1 year ago
TherapeuticsMD Announces Third Quarter 2023 Financial Results
BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the third quarter ended September 30, 2023. “As the Company continues its transition into a royalty-based business, we remain committed to cost control to maximize the value of our royalty assets,” stated Marlan D. Walker, Chief Executive Officer of TherapeuticsMD. Third Quarter 2023 Financial Res.
TherapeuticsMD Announces Third Quarter 2023 Financial Results
Charts implemented using Lightweight Charts™